Greater China Sector Update | Automobile China’s PV sales rebounded last week, with PEV growth surging from below 5% to over 30% due to subsidies and new models. Geely and XPeng led, while BYD and Li Auto lagged. Vehicle exports rose 26% yoy in August, driven by gains in the EU, Africa, and Middle East. Maintain MARKET WEIGHT. Top BUYs: CATL (target price raised to Rmb520) and Geely. Top SELLs: BYD and Li Auto. Sector Update | Healthcare Falling interest rates are expected to significant...
We attended BCH’s 2Q25 analyst meeting, and the tone was positive. Management updated that the return of Kuwaiti patients is drawing nearer. BCH will not set any additional provisions on the outstanding receivables of Kuwaiti patients as the Kuwaiti officials have indicated a strong commitment to pay off the debt. The outlook in 3Q25 will be challenging, as we had expected, given several headwinds, but the earnings outlook in 4Q25 remains promising. Maintain BUY. Target price: Bt20.00.
GREATER CHINA Results China Mengniu Dairy (2319 HK/BUY/HK$15.84/Target: HK$21.70) 1H25: Revenue slightly misses but operating profit beats; expect mid-to-high single-digit revenue decline for 2025. China Resources Gas (1193 HK/BUY/HK$19.05/Target: HK$22.60) 1H25: In line; from earnings drag to guidance-driven re-rating; upgrade to BUY. ECARX Holdings Inc (ECX US/BUY/US$1.60/Target: US$3.40) 2Q25: Net loss widens; recovery expected in 2H25. Maintain...
BCH reported a net profit of Bt388m in 2Q25 (+38.1% yoy, +17.2% qoq) which is in line with our forecast but above the consensus. Top-line grew by 5.7% yoy which is within our expectations, driven by revenue growth from OPD and SSO patients, and mainly contributed by the annual extra revenue of Bt77.5m. The 3Q25 outlook is challenging, but we are positive on BCH for 4Q25, supported by strong growth prospects from the low base in 4Q24. Maintain BUY. Target price: Bt17.50.
KEY HIGHLIGHTS Results Bangkok Chain Hospital (BCH TB/BUY/Bt14.10/Target: Bt17.50) 2Q25: Reported strong earnings as expected. Update Central Pattana (CPN TB/BUY/Bt54.50/Target: Bt79.60) Favourable 2H25 outlook anchored by core business resilience. Central Plaza Hotel (CENTEL TB/BUY/Bt27.00/Target: Bt33.00) Expect a gradual improvement in outlook. Charoen Pokphand Foods (CPF TB/HOLD/Bt24.40/Target: Bt24.00) 2Q25 earnings in line; 3Q25 earnings momentum to soften. The Erawan ...
BCH is expected to report a net profit of Bt378m in 2Q25 (+36.5% yoy, +17.7% qoq). Top-line should come in at Bt2.96b (+3.7% yoy, +2.0% qoq), mainly driven by a growth in revenue from outpatient department (OPD) patients due to the treatment of COVID-19 and the rain in May 25 as well as a strong growth in social security (SSO) patient numbers. The 3Q25 outlook is challenging, but we remain optimistic on BCH in 2H25 for its strong growth outlook from a low base in 4Q24. Maintain BUY. Target ...
KEY HIGHLIGHTS Results Bangchak Corporation (BCP TB/BUY/Bt34.00/Target: Bt45.00) 2Q25: Net loss as expected but a sharp rebound is likely in 2H25. Bangchak Sriracha (BSRC TB/BUY/Bt5.00/Target: Bt7.00) 2Q25: Huge inventory loss results in net loss in 2Q25. PTT Oil & Retail Business (OR TB/BUY/Bt12.90/Target: Bt20.00) 2Q25: Net profit in line with our forecast but 14% below consensus’. Upgrade to BUY. Tidlor Holdings (TIDLOR TB/HOLD/Bt18.30/Target: Bt20.00) 2...
GREATER CHINA Economics Trade: July’s data beats expectations, further near-term strength likely. Sector Automobile: Weekly: YOY PV sales growth remains negative for three straight weeks. Maintain MARKET WEIGHT on the sector. Top BUYs: CATL, Geely and Tuopu. Initiate Coverage Zhejiang Sanhua Intelligent Controls Co (002050 CH/BUY/Rmb27.37/Target: Rmb36.50): Innovative Thermal management leader driving sustainable growth. Initiate coverage with BUY. Target price: Rmb36.50 for A-share, HK$40.00 fo...
GREATER CHINA Economics PMI Modest recovery with construction rebound. Sector Macau Gaming Jun 25 GGR beat consensus by 9%; GGR has regained momentum in recent months. INDONESIA Small/Mid Cap Highlights MAP Aktif Adiperkasa (MAPA IJ/NOT RATED/Rp700) Expanding active lifestyle retail business; 1Q25 NPAT up 21% yoy. MAL...
We attended BCH’s 1Q25 analyst meeting, and the tone was positive. Management clarified that SSO’s recent high budget spending will not impact the current AdjRW>2 rate of Bt12,000 per head, resolving investors’ concerns over the past few days. Despite a slight downward revision in its 2025 guidance due to the weak economy, we still expect a robust yoy earnings growth in 2Q25. Maintain BUY. Target price: Bt17.50.
GREATER CHINA Results Kuaishou Technology (1024 HK/BUY/HK$48.75/Target: HK$70.00): 1Q25: Results in line; poised for encouraging contribution from Kling AI in 2025. Link REIT (823 HK/BUY/HK$40.90/Target: HK$44.90): FY25: Earnings beat expectations; cautious outlook for FY26. PDD Holdings (PDD US/SELL/US$119.24/Target: US$90.00): 1Q25: Earnings miss expectations; increased platform investment to weigh on profitability. Downgrade to SELL. Xiaomi Corp (1810 HK/BUY/HK$51.55/Target: HK$69.90): 1Q25: ...
In 1Q25, earnings under our coverage are at Bt201.14b (-0.1% yoy, +46.2% qoq). The qoq increase was due to seasonality. The banking, telecommunications and consumer staples sectors reported remarkable results. For 2025 we reduce earnings growth by 3.8%, but opportunities remain in domestic and external plays. Overall, we lower 2025F EPS to Bt80 from Bt94and our SET target to 1,280 (from 1,500 in 1Q25) based on 16.0x forward PE. Top picks are ADVANC, RATCH, BCH, IVL, PTTGC.
BCH reported a net profit of Bt321m in 1Q25 (+0.8% yoy, +37.9% qoq), which is in line with our and consensus forecasts. The top-line is at Bt2.9b (+2.1% yoy, +5.1% qoq). The main contributors are revenue from outpatient department (OPD) patients which grew 4% yoy and from social security (SSO) patients that grew 3.7% yoy. We are bullish on BCH, as we expect it to be able to grow stronger yoy from the low base last year. Maintain BUY. Target price: Bt20.00.
GREATER CHINA Update Foxconn Industrial Internet (601138 CH/BUY/Rmb19.22/Target: Rmb25.30) 2Q25 guidance in line; GB200/GB300 smooth production ramp as the key driver for 2025-26. Maintain BUY. INDONESIA Strategy JCI rallies from global tailwinds Market rebound gains momentum amid global tailwinds and rate cut hopes. MALAYSIA Results Maxis (MAXIS MK/BUY/RM3.76/Target: RM4.20) 1Q25: Strong set of results; earnings d...
We expect a net profit of Bt319m in 1Q25 (+0.0% yoy, +36.8% qoq). Top-line should come in at Bt2.9b (+2.0% yoy, +5.0% qoq), mainly driven by revenue growth from OPD patients, which should offset the loss of revenue from Kuwaiti patients compared to last year. We are optimistic on BCH, as the growth outlook for 2Q25 seems promising and several hospitals have shown a solid recovery in performance. Maintain BUY. Target price: Bt20.00.
GREATER CHINA Economics A New Round of Policy Support Positive for the economy, but mostly priced in. Results BeiGene (6160 HK/BUY/HK$141.00/Target: HK$220.00) 1Q25: Results beat; reaches profitability with adjusted net earnings of US$136m. INDONESIA Results XLSMART Telecom Sejahtera (EXCL IJ/HOLD/Rp2,180/Target: Rp2,400) 1Q25: EBITDA down 3% yoy. Downgrade to HOLD. MALAYSIA Results SD Guthrie (SDG MK/HOLD/RM...
GREATER CHINA Strategy Alpha Picks: May Conviction Calls Add Alibaba, Innovent, Shuanghuan, Trip.com to our BUY list. Take profit on JBM Healthcare and CR Land. Sector Aviation Airlines: 1Q25 results below expectations. Weak fuel prices to support full-year performance. Maintain UNDERWEIGHT. INDONESIA Strategy 1Q25 Results Recap ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.